COMMUNIQUÉS West-GlobeNewswire
-
Cingulate Announces U.S. Patent Issuance for CTx-2103, Further Validating PTR™ Technology Platform
19/11/2026 -
Acentra Health CEO Todd Stottlemyer Named 2026 Virginia Business Icon Honoree
19/11/2026 -
Hennick Humber Hospital Foundation’s Big Bash for Humber Raises $3.9 Million NET to Bring Life-Saving Cardiac Care Closer to Home
19/11/2026 -
The Silk Road Gets a Spidey Genetic Upgrade
19/11/2026 -
Sienna Senior Living Introduces Virtual Primary Care Benefit for Employees and Their Families
19/11/2026 -
Researchify Health Announces Five-Year Plan to Engage 100 Million Patients Each Month About Clinical Trials
19/11/2026 -
GATC Health Joins Bipartisan Panel at U.S. Capitol on the Future of Human-Relevant Drug Development
19/11/2026 -
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
19/11/2026 -
Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)
19/11/2026 -
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting
19/11/2026 -
Remix Therapeutics Announces Updated Positive REM-422 Phase 1 Data in Adenoid Cystic Carcinoma at 2026 EORTC-NCI-AACR Symposium
19/11/2026 -
Korro to Participate in Upcoming Investor Conferences
19/11/2026 -
Adagene Announces First Patient Dosed in Phase 1 Study of ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
19/11/2026 -
Evaxion announces strategy and business update and third quarter 2026 financial results
19/11/2026 -
In a Co-Managed Customer Support Model, Growing Companies Can Keep Control of Training While a Partner Runs Staffing
19/11/2026 -
Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study
19/11/2026 -
Verano Celebrates Grand Opening of MÜV Tarpon Springs, the Company’s 89th Florida Location, 166th Nationwide
19/11/2026 -
Opus Genetics Announces First Participant Dosed in Phase 1/2 Clinical Trial of OPGx-RDH12 Gene Therapy for Rare Inherited Childhood Blindness
19/11/2026 -
Enable Injections and ARespo Biopharma Announce Strategic Partnership
19/11/2026
Pages